Narcolepsy

The PBS subsidises armodafinil and modafinil for patients with narcolepsy.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with armodafinil and modafinil under the National Health Act 1953, section 85 for patients with narcolepsy.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing armodafinil and modafinil.

Treatment specifics

To be eligible for PBS subsidised treatment with these medicines, patients must be treated by a qualified sleep medicine practitioner or a neurologist.

Armodafinil and modafinil are not PBS subsidised when used in combination with each other or with PBS subsidised dexamfetamine sulfate.

Authority applications

Applying for initial treatment for narcolepsy without cataplexy

Apply for initial authority approval to prescribe PBS subsidised armodafinil and modafinil to treat narcolepsy without cataplexy in writing and either:

All written applications must include the completed:

Applying for initial treatment for narcolepsy with cataplexy

Applications for initial authority approval to prescribe PBS subsidised armodafinil and modafinil to treat narcolepsy with cataplexy can be made either:

Applying for continuing or change of treatment

Apply for continuing or changing authority approval to prescribe PBS subsidised armodafinil or modafinil to treat narcolepsy either:

Applications can be made by the patient’s medical practitioner if the patient has previously been issued an authority prescription for these medicines.

Further information

Call the PBS Complex Drugs Programs enquiry line for further information.

Page last updated: 1 November 2020